CSL Limited (CSL.AX)

ASX: CSL.AX · 实时价格 · USD

172.32

-1.56 (-0.90%)

收盘价： Aug 28, 2026, 6:10 AM

股价、关键数字和最新消息，都在这一页。

-0.90% (1D)

暂无数据

买价	172.29
市值	82.53B
营收（TTM）	15.8B
净利润（TTM）	-2.58B
	0.09
	-7.44
	n/a
	18.5
市净率（TTM）	4.01
市销率（TTM）	5.22
财报日期	Feb 9, 2027

卖价	173
成交量	1,121,442
20日均量	1,728,006
开盘价	172.20
前收盘价	173.88
日内区间	171.32 - 174.87
52周区间	90.00 - 222.47
分析师	n/a
目标价	n/a
分红	$4.09 (2.37%)
除息日	2026年9月9日

关于 CSL.AX

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqi...

[阅读更多]

行业 Biotechnology

板块 Healthcare

上市日期 May 31, 1994

员工人数 29,000

交易所 ASX

股票代码 CSL.AX

官网 https://www.csl.com

公司完整简介

财务表现

2026年，CSL的营收为15.7B，较上一年的15.43B增长1.74%。净利润为-2.58B，下降-185.91%。

财务数据以AUD计财务报表

下次财报发布时间

CSL Limited 的下次财报预计于 Feb 9, 2027, 开盘前。
分析师预计营收为 ... 升级

新闻

1月前 · Investing.com

Australia to challenge Trump’s new 12.5% tariff, says PM Albanese

Investing.com -- Australian Prime Minister Anthony Albanese said he would raise Washington’s new 12.5% tariff on Australian goods directly with U.S. President Donald Trump, Reuters reported.

2月前 · The Wall Street Journal

European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked

The committee is recommending that no new patients start treatment with Tavneos and that existing patients be switched to suitable alternatives.

3月前 · Proactive

Imugene strengthens board with biotech and pharma appointments

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has appointed Dr Charmaine Gittleson and Michael Kotsanis as non-executive directors as part of a board enhancement process aimed at supporting the company’s ...

3月前 · Simply Wall St.

3 ASX Dividend Stocks Yielding Up To 4.2%

As the Australian market grapples with global uncertainties and fluctuating commodity prices, investors are increasingly seeking stability amidst the volatility. In such an environment, dividend stock...

3月前 · GuruFocus.com

CSL Plunges 22% After Cutting Outlook And Flagging $5 Billion Impairments

CSL now expects weaker full-year revenue and profit as plasma, China pricing, and Vifor pressures weigh on performance.

第 1 页，共 2 页

CSL Limited (CSL.AX)

关于 CSL.AX

财务表现